Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply

Aliment Pharmacol Ther. 2021 Feb;53(3):445-446. doi: 10.1111/apt.16227.

Authors

Silvio Danese¹, Kavitha Subramaniam², Jan Van Zyl³, Shashi Adsul⁴

Affiliations

¹ IBD Center, Humanitas Clinical and Research Center - IRCCS, and Humanitas University, Department of Biomedical Sciences, Milan, Italy.
² Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, ACT, Australia.
³ Gastroenterology Unit, University of the Free State, Bloemfontein, South Africa.
⁴ Takeda Pharmaceuticals International AG, Zurich, Switzerland.

PMID: 33428255
DOI: 10.1111/apt.16227

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Data Analysis*
Humans
Inflammatory Bowel Diseases* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
vedolizumab